Alvotech ALVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALVO is a good fit for your portfolio.
News
-
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
-
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment
-
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
-
Alvotech Shares Rise Premarket After Humira Biosimilar Approval
-
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
-
Alvotech Shares Climb After FDA Concludes Facility Inspection
-
Teva Pharmaceuticals and Alvotech expand biosimilars partnership
-
Alvotech Shares Rebound 20% After FDA Letter Selloff
Trading Information
- Previous Close Price
- $14.15
- Day Range
- $14.20–14.30
- 52-Week Range
- $6.70–18.00
- Bid/Ask
- $14.52 / $22.60
- Market Cap
- $3.98 Bil
- Volume/Avg
- 39,632 / 281,444
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 35.37
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 999
- Website
- https://www.alvotech.com
Comparables
Valuation
|
Metric
|
ALVO
|
ICVX
|
TLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 118.49 |
Price/Book Value | — | 3.30 | 32.72 |
Price/Sales | 35.37 | — | 9.67 |
Price/Cash Flow | — | — | 201.13 |
Price/Earnings
ALVO
ICVX
TLX
Financial Strength
|
Metric
|
ALVO
|
ICVX
|
TLX
|
|---|---|---|---|
Quick Ratio | 0.38 | 17.59 | 1.19 |
Current Ratio | 0.75 | 18.06 | 1.43 |
Interest Coverage | −3.93 | — | 1.15 |
Quick Ratio
ALVO
ICVX
TLX
Profitability
|
Metric
|
ALVO
|
ICVX
|
TLX
|
|---|---|---|---|
Return on Assets (Normalized) | −44.01% | −29.30% | 3.71% |
Return on Equity (Normalized) | — | −31.87% | 11.73% |
Return on Invested Capital (Normalized) | −108.40% | −34.69% | 18.08% |
Return on Assets
ALVO
ICVX
TLX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Lfrdrjxx | Pvxy | $73.0 Bil | |
MKKGY
| Merck KGaA ADR | Jgnntbgs | Srrytv | $69.8 Bil | |
HLN
| Haleon PLC ADR | Bzctchp | Fnczg | $37.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Mgrwdctp | Rzm | $14.6 Bil | |
VTRS
| Viatris Inc | Hrwpjngsm | Ftg | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Pkzgnlnm | Qww | $12.6 Bil | |
CTLT
| Catalent Inc | Rlhfkrm | Hgxgkfw | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Vbgpxgsxj | Pdhn | $4.4 Bil | |
CURLF
| Curaleaf Holdings Inc | Xrzlgwry | Cykzn | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Wlfrqqbp | Lhmbwfz | $3.6 Bil |